Dan Wang

Dr. Dan Wang is an Assistant Professor at the University of Massachusetts Chan Medical School, affiliated with the T.H. Chan School of Medicine's Genetic and Cellular Medicine Department. He leads the Wang Lab at the Horae Gene Therapy Center and the RNA Therapeutics Institute, focusing on advancing AAV-based gene therapy for neurological and metabolic diseases. His research integrates molecular approaches such as genome editing and RNA-based therapies with platform technologies like AAV vector production and animal modeling.

Education:

• Bachelor's in Life Sciences from Fudan University, Shanghai
• PhD in Genetics & Genomic Sciences from the University of Alabama

Research Interests:

Dr. Wang's work centers on translational gene therapy using adeno-associated virus vectors. Key areas include:
- Targeting diseases like FOXG1 syndrome, maple syrup urine disease, and ALS/FTD
- Developing AAV capsid variants for tissue-specific delivery
- Optimizing AAV production and quality control
- Exploring CRISPR-based genome editing and RNA therapies. His lab has pioneered innovations in high-purity vector production and liver-detargeted CNS delivery.

Publications: Over 80 peer-reviewed articles, with recent focus on AAV vector engineering, gene replacement therapy efficacy, and preclinical models for neurological disorders. Notable contributions include foundational work on suppressor tRNA therapies and systemic gene correction in metabolic diseases.

Labs/Teams: Directs the Wang Lab, collaborating with the Gao Lab and other centers. Key team members include postdoctoral associates (e.g., Hao Chang, Ailing Du) and research scientists (e.g., Gong Chen).